Morgan Stanley underweight on Sun Pharma; SPARC's Baclofen GRS fails in phase III study

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Morgan Stanley has put underweight rating on Sun Pharmaceutical Industries as SPARC's Baclofen GRS has failed to meet primary end points in the pivotal phase III study.

Sun Pharma is a manufacturing/marketing partner of SPARC on a product-by-product & merit-based selection process.

Baclofen GRS was the key product in SPARC's pipeline.

Meawhile, Elepsia XL and Xelpros are mid-sized opportunities in SPARC's pipeline, which are delayed due to Halol issues.

At 11:26 hrs Sun Pharmaceutical Industries was quoting at Rs 529.50, down Rs 0.90, or 0.17 percent.

The share price declined 26.7 percent in the last one year.

Posted by Rakesh Patil